Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750903 | 1.00 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL187408 | 1.00 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| Bromide SCHEMBL6544002 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29036064 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29036066 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Bicarbonate SCHEMBL7972998 | 0.96 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL258790 | 0.93 | ACE (0.50) | ACEREN | |
| SCHEMBL6478173 | 0.93 | ACE (0.50) | ACEREN | |
| SCHEMBL1950731 | 0.93 | ACE (0.50) | ACEREN | |
| Bicarbonate SCHEMBL7973000 | 0.92 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110621664-A | Novel piperidine-2, 6-dione derivatives and uses thereof | 韩国化学研究院 | 2019-12-27 | — | — | CN | claimed |
| EP-4460506-A1 | ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF | University of Maryland, Baltimore (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389747-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2024-06-26 | — | — | EP | disclosed |
| CN-115477606-B | Method for rapidly converting ester into alkyne | 中国科学院兰州化学物理研究所 | 2024-01-26 | — | — | CN | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| WO-2023133507-A1 | ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| CN-115477606-A | Method for quickly converting ester into alkyne | 中国科学院兰州化学物理研究所 | 2022-12-16 | — | — | CN | disclosed |
| EP-3331532-B1 | SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | NATIONAL INSTITUTES OF HEALTH | 2007-11-01 | — | — | US | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1150969-B1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI SYNTHELABO (FR) | 2002-11-20 | — | — | EP | disclosed |
| US-6413984-B1 | REACTING PYRROLIDINE OR PIPERIDINE ALDEHYDE WITH METAL QUINO-LINE; OPTIONAL DEHYDROXYLATION AND/OR AMINE SUBSTITUTION; MIGRAINES, VASOCONSTRICTION OF NASAL MUCOSA, GASTROINTESTINAL DISORDERS, VEINOUS INSUFFICIENCY | SANOFI-SYNTHELABO (FR) | 2002-07-02 | — | — | US | disclosed |
| EP-1150969-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046219-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | disclosed |
| WO-1998033793-A1 | α-AZACYCLOMETHYL BENZOTHIOPHENE AND α-AZACYCLOMETHYL BENZOFURANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| US-5321021-A | Tricyclic pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1994-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | PRKCA, PRKCE, PRKCB | ACE 3029/4885REN 2765/4885LMNA 1651/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ACE 1766/4885REN 1336/4885LMNA 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.